As nausea probably occurs at the peak of plasma concentrations of GLP-1 [80], the lower incidence of nausea with liraglutide compared with exenatide BID may be explained by its sustained release formulation and tachyphylaxia resulting from the sustained plasma level [55, 79, 81]. This evidence concerns the gene GLP1R and Nausea.